To evaluate the presence of dopamine-2(DA2) binding sites in pheochromocytoma tissue, we performed binding studies and light microscopy autoradiography on sections of 7 different tumors. 3-H-Spiroperidol, a DA2 ligand, bound specifically to tumor sections with a (mean +/- SD) Kd value of 1.93 +/- 0.62 nmol/L. Binding site density (Bmax) was 29.16 +/- 2.33 fmol/mg tissue. Light microscopy autoradiography showed a nonhomogenous localization of silver grains within chromaffin cells. The specific binding was about 50% of total. To investigate whether DA2 binding sites found on pheochromocytoma cells might modulate catecholamine (CA) release, we studied the effects of oral bromocriptine (2.5 mg) on circulating CA of 5 patients with pheochromocytoma. In these patients bromocriptine caused a decrease in blood pressure (P less than .05) but no significant change in plasma CA. Our study shows the presence of DA2 binding sites on tumoral chromaffin tissue. As bromocriptine, a DA2 receptor agonist, was not able to modify tumor CA secretion, the functional role, if any, played by these binding sites on tumor secretion is still to be clarified.

Dopamine modulation of pathological human chromaffin tissue.

AMENTA, Francesco;
1990-01-01

Abstract

To evaluate the presence of dopamine-2(DA2) binding sites in pheochromocytoma tissue, we performed binding studies and light microscopy autoradiography on sections of 7 different tumors. 3-H-Spiroperidol, a DA2 ligand, bound specifically to tumor sections with a (mean +/- SD) Kd value of 1.93 +/- 0.62 nmol/L. Binding site density (Bmax) was 29.16 +/- 2.33 fmol/mg tissue. Light microscopy autoradiography showed a nonhomogenous localization of silver grains within chromaffin cells. The specific binding was about 50% of total. To investigate whether DA2 binding sites found on pheochromocytoma cells might modulate catecholamine (CA) release, we studied the effects of oral bromocriptine (2.5 mg) on circulating CA of 5 patients with pheochromocytoma. In these patients bromocriptine caused a decrease in blood pressure (P less than .05) but no significant change in plasma CA. Our study shows the presence of DA2 binding sites on tumoral chromaffin tissue. As bromocriptine, a DA2 receptor agonist, was not able to modify tumor CA secretion, the functional role, if any, played by these binding sites on tumor secretion is still to be clarified.
1990
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11581/243015
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact